I really would like to uplist from strength from a much higher price. However, you bring up a good point. We know we are going to have some strong catalysts, so the 'strength' is there from that perspective. I would much prefer exposure of those catalysts on the Nasdaq regardless of how big a RS would have to be. Institutions would be able to play the game and support the share price.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links